**Abstract**

**Background:** The possible dose-dependency for the antidepressant effect of selective serotonin reuptake inhibitors (SSRIs) remains controversial. We have conducted the first comprehensive patient level mega-analysis exploring this issue, one incentive being to address the possibility that inclusion of low-dose arms in previous meta-analyses may have caused an underestimation of the efficacy of these drugs.

**Methods:** Pooled analyses of all company-sponsored, acute-phase, placebo-controlled, fixed-dose trials using the Hamilton Depression Rating Scale (HDRS) conducted to evaluate the effect of citalopram, paroxetine, or sertraline in adult major depression (n=2859). The single item depressed mood, which has proven a more sensitive measure to detect an antidepressant signal than the conventional one, i.e. the sum score of all HDRS items, was designated primary effect parameter

**Results:** Doses below or at the lower end of the dose range usually recommended (citalopram: 10-20mg, paroxetine: 10mg; sertraline: 50mg) were superior to placebo but inferior to higher doses. In contrast, among doses above these, there was no indication of a dose-response relationship. The effect size after exclusion of suboptimal doses was of a more respectable magnitude (0.5) than that usually attributed the antidepressant effect of the SSRIs. With respect to the depressed mood item, high-dose and low-dose both outperformed placebo already after one week.

**Conclusions:** The observation that low doses are less effective than higher ones challenges the oft-cited view that the effect of the SSRIs is not dose-dependent and hence not caused by a specific, pharmacological antidepressant action. We suggest that inclusion of suboptimal doses in previous meta-analyses has led to an underestimation of the efficacy of these drugs. Moreover, the finding that both low-dose and high-dose SSRI reduce depressed mood more effectively than placebo already during the first week of treatment may have implications for our understanding of the mechanism of action of these drugs.
